Framework Journal · one stock, one dated entry

Recorded 2026-07-27 · Permanent

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

In plain words · Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide.

The label
Markup

read at $258.03

Natera Inc holds its Markup at $258.03.

PHINPOOPSC
  • PHPhase · the trend structure carries the Markup label
  • INInsiders · no filings inside 60 days, left as found
  • POPositioning · no disclosures inside 60 days, left as found
  • OPOptions · no verdict drawn today, left as found
  • SCScreen · passes the values gate
  • edge confirmed
  • edge broken
  • edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2026-07-27
PhaseMarkup
Quantitative stateConsolidating, no directional conviction, held for 48 days
Price$258.03
ValuationN/A trailing · -1,260.59 forward price to earnings
Values screenPASS · score 70.0
Beta1.51

The opportunity · what the numbers say it is worth

Read at
$258.03
N/A P/E · -1,260.59 fwd
Our fair value
$290.00
12% discount
Analyst target (avg)
$290.00
+12% to current
Target low $193.00Analyst target rangeTarget high $330.00
▲ current $258.03 · | average target

Price history & projections · where it has been, where the models see it going

$353$189$26TODAY5y agoPROJECTIONAnalyst high$330.00 +52%Analyst avg$290.00 +34%Our fair value$290.00 +34%Conservative$193.00 -11%

The valuation journey · where the price sits against fair value and the Street

Current
$258.03
you are here
Conservative
$193.00
-25%
Analyst avg
$290.00
+12%
Our fair value
$290.00
+12%
Analyst high
$330.00
+28%

Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.

Reading the gap · Both our model and the analysts see meaningful upside from here.

Revenue growth38.80%
Profit margin-9.05%
Debt to equity13.53
Analyst consensusStrong Buy · 21 covering

Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.

The values screen, explained · five checks, plain English

This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:

The common standard · AAOIFI
Used by most halal investing apps
✓ PASSES
Our stricter standard · asset-based
The one Titan applies
✓ PASSES

What these two standards are, and how they differ →

  • Business activity Its core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending. Pass
  • Debt load Interest-bearing debt is of its assets, above the one-third ceiling the screen allows. Fail
  • Interest-bearing cash Interest-bearing cash and securities are of assets, above the one-third limit. Fail
  • Receivables Money owed to the company is of assets, above the 49% limit. Fail
  • Revenue purity of revenue comes from non-compliant sources, over the 5% line. Fail

Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.

The business, in plain words · what the numbers mean

Tracking hidden cancer with a simple blood test

When a patient finishes cancer treatment, the real worry is whether stray cells will return. Natera turns that fear into a blood test that spots tiny traces of disease long before scans can. Revenue is rising 39 percent a year, the test has a narrow moat, and the shares sit just 3 percent below our fair value.

Yet the business still loses money, shown by a negative 9 percent profit margin and minus 15 percent return on equity. Forward earnings sit at a deeply negative multiple, so any slip in growth or reimbursement would hurt fast. The ethical screen is clear, but the thin margin of safety leaves little room for error.

Analysis, not advice.

The fundamentals · plain-English read
Forward P/E-1,260.6x
Revenue growth38.8%
strong top-line growth
Profit margin-9.0%
currently unprofitable
Return on equity-15.0%
not currently earning a positive return on equity
Debt to equity0.14
minimal debt — a conservative balance sheet
Current ratio2.96
comfortably covers its short-term bills
Beta1.51
much more volatile than the market
Market cap$37.0B
Employees6,135

The risks · The things to watch: it already moves more than the market on an average day.

Plain-English interpretation of our own screen data. Analysis, not advice.

Latest news · what the market is reading on NTRA

Headlines from third-party outlets, linked for reference — not our reporting, not advice.

Related securities · others in NTRA's space worth a look

Screened names in the same industry · explore each on its own page.

The trader read · the latest dated commentary

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (20 analysts) rates it buy, with a mean price target of $260. Entered 2026-07-18 · Markup

The dated journal · newest first, never edited

2026-07-18 Markup $212.07 +0.0% Entry 3

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is holding around 9% above its long-term trend line with momentum reading bullish. Over the past year the shares are up 31%. Our forward projection puts the odds of a 10% gain over the next month near 35%. The street (20 analysts) rates it buy, with a mean price target of $260.

2026-07-03 Markup $212.07 +0.0% Entry 2

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.

2026-07-02 Markup $212.07 Entry 1

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows good risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

The political ledger · congressional disclosures

Disclosures naming NTRA
DatePoliticianPartyTypeAmount
30 Apr2026 Dave McCormick Republican sell 500K–1M
2 Jun2026 John Curtis Republican sell 1K–15K

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $199.14 +9.0% · $1,090 +9.0%
2 months $193.03 +12.5% · $1,125 +12.5%
3 months $190.31 +14.1% · $1,141 +14.1%
6 months $231.05 -6.0% · $940 -6.0%
1 year $165.22 +31.4% · $1,314 +31.4%
2 years $111.66 +94.5% · $1,945 +94.5%
3 years $48.38 +348.8% · $4,488 +348.8%
5 years $103.88 +109.0% · $2,090 +109.0%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever NTRA does next, these words stay.

Natera Inc · NTRA · Markup · $258.03
Recorded 2026-07-27 · before the outcome · scored mechanically

Get our weekly market brief free.